The price of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) closed at $3.37 in the last session, down -0.88% from day before closing price of $3.40. In other words, the price has decreased by -$0.0300 from its previous closing price. On the day, 1225578 shares were traded. KPTI stock price reached its highest trading level at $3.4750 during the session, while it also had its lowest trading level at $3.2950.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
We take a closer look at KPTI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.50 and its Current Ratio is at 3.60.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on January 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $8.
On November 04, 2022, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $7 to $10.
JP Morgan Upgraded its Underweight to Neutral on February 09, 2022, while the target price for the stock was maintained at $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 04 when Paulson Richard A. sold 3,922 shares for $3.27 per share. The transaction valued at 12,825 led to the insider holds 608,605 shares of the business.
Paulson Richard A. sold 3,490 shares of KPTI for $18,043 on Dec 05. The President and CEO now owns 612,527 shares after completing the transaction at $5.17 per share. On Nov 04, another insider, Paulson Richard A., who serves as the President and CEO of the company, sold 3,493 shares for $4.54 each. As a result, the insider received 15,858 and left with 616,017 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.58.
Stock Price History:
Over the past 52 weeks, KPTI has reached a high of $14.73, while it has fallen to a 52-week low of $2.45. The 50-Day Moving Average of the stock is 3.6334, while the 200-Day Moving Average is calculated to be 4.8425.
Shares Statistics:
According to the various share statistics, KPTI traded on average about 2.73M shares per day over the past 3-months and 1.93M shares per day over the past 10 days. A total of 80.21M shares are outstanding, with a floating share count of 74.06M. Insiders hold about 1.40% of the company’s shares, while institutions hold 88.20% stake in the company. Shares short for KPTI as of Oct 13, 2022 were 13.69M with a Short Ratio of 21.67M, compared to 14.26M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 17.16% and a Short% of Float of 20.43%.
Earnings Estimates
The company has 9 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.57 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.73, while EPS last year was -$0.69. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.3 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$1.78 and -$2.33 for the fiscal current year, implying an average EPS of -$2.1. EPS for the following year is -$1.46, with 9 analysts recommending between -$0.81 and -$1.9.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $34.56M. It ranges from a high estimate of $36.39M to a low estimate of $32.7M. As of the current estimate, Karyopharm Therapeutics Inc.’s year-ago sales were $25.8M, an estimated increase of 34.00% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $38.01M, a decrease of -69.90% less than the figure of $34.00% in the same quarter last year. There is a high estimate of $41M for the next quarter, whereas the lowest estimate is $35.11M.
A total of 9 analysts have provided revenue estimates for KPTI’s current fiscal year. The highest revenue estimate was $164.54M, while the lowest revenue estimate was $135.03M, resulting in an average revenue estimate of $157.23M. In the same quarter a year ago, actual revenue was $209.82M, down -25.10% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $176.16M in the next fiscal year. The high estimate is $238.77M and the low estimate is $143M. The average revenue growth estimate for next year is up 12.00% from the average revenue estimate for this year.
